ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 27

Altered Inflammatory Response of Macrophages in the Fosl-2 Transgenic Mouse Model of Systemic Sclerosis

Chantal Rufer 1, Michal Rudnik1, Siim Uhtjärv 1, Mara Stellato 1, Florian Renoux 2, Oliver Distler 3 and Gabriela Kania 1, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 2Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, 3Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: , ,

Session Information

Date: Sunday, November 10, 2019

Title: Innate Immunity Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Fos-like 2 (Fosl-2) is a transcription factor belonging to the Fos family of proteins which is part of the AP-1 transcription complex. The Fosl-2 transgenic (tg) mouse model has been shown to develop a similar phenotype to patients with SSc, such as vascular changes, dysregulation of innate and adaptive immunity, and fibrosis of the skin and visceral organs. Although the etiology is yet to be found, various studies have indicated immune cells, such as macrophages, to be important contributors to the pathogenesis of SSc. In this study, we aimed to determine the role of Fosl-2 expression in macrophages.

Methods: Bone marrow from Fosl-2 tg and wild type (wt) mice was isolated and differentiated into macrophages by stimulation with recombinant mouse macrophage colony stimulating factor (M-CSF) (20 ng/ml) for 7 days. The bone marrow-derived macrophages (BMDM) were stimulated with LPS (10 ng/ml) or IL-4 (10 ng/ml) for various time points. Expression of Fosl-2 and cJun was checked by Western blot. Levels of inflammatory cytokines IFN-g (wt n=12, tg n=15), TNF-α (wt n=9, tg n=11), IL-1β (wt n=8, tg n=9), IL-6 (n=7), and anti-inflammatory markers MRC1 (wt n=9, tg n=11) and CCL22 (n=8) were determined by qPCR and ELISA. To assess the production of nitric oxide, BMDM were stimulated with LPS (10 ng/ml) (n=17) or LPS + IFN-g (10 ng/ml) (n=9) and a Griess assay was performed. An arginase assay was conducted to evaluate urea concentration post stimulation (wt n=7, tg n=3).

Results: We observed induction of Fosl-2 after LPS and IL-4 stimulation in wt and Fosl-2 tg BMDM, with the peak of expression at 4 to 6 hours in wt mice. Tg mice show a higher induction of Fosl-2 after LPS stimulation than wt mice. After LPS stimulation, Fosl-2 tg BMDM showed a decreased mRNA expression of IFN-g (p< 0.0001), TNF-α (p=0.0036), as well as a tendency towards decreased expression of IL-1β. Protein levels of IL-6 and TNF-α appeared to peak around 6h post LPS stimulation and were decreased in tg BMDM compared to wt BMDM (p=0.0044 and p=0.02555). Fosl-2 tg BMDM were characterized by lower concentrations of NO after LPS stimulation (p=0.0061) and further decreased after co-stimulation with IFN-g (p=0.0118), in comparison to wt mice. After stimulation with IL-4, when comparing wt to tg BMDM, MRC1 (p=0.0007) was downregulated and CCL22 (p=0.0361) upregulated.

Conclusion: Our data indicates the involvement of Fosl-2 in the regulation of the inflammatory response of macrophages. Decreased levels of inflammatory cytokines suggest a possible alternative activating phenotype-promoting role of Fosl-2. Alternative activation of macrophages induces fibrosis, thus bringing Fosl-2 and macrophages into the spotlight regarding the development of fibrosis in SSc.

Disclosure: C. Rufer, None; M. Rudnik, None; S. Uhtjärv, None; M. Stellato, None; F. Renoux, None; O. Distler, A. Menarini, 5, Abbvie, Acceleron, 5, Acceleron Pharma, 5, Actelion, 2, 5, 8, Actelion Pharmaceuticals, 2, 5, 8, 9, Amgen, 5, AnaMar, 2, 5, Bayer, 2, 5, 8, 9, Biogen Idec, 2, 5, Blade Therapeutics, 5, Boehringer Ingelheim, 2, 5, 8, 9, Catenion, 5, 9, ChemomAb, 2, 5, ChemomAB, 5, CSL Behring, 5, Ergonex, 5, espeRare Foundation, 2, 5, Genentech/Roche, 2, 5, GlaxoSmithKline, 5, GSK, 2, 5, Holds Patent mir-29 for the treatment of systemic sclerosis, 9, Inventiva, 2, 5, iQvia, 5, Italfarmaco, 2, 5, Italfarmco, 5, Lilly, 2, 5, med, 5, 8, medac, 5, Medac, 2, 5, MedImmune, 2, 5, Medscape, 5, 8, 9, Menarini, 8, Mepha, 8, Mitsubishi Tanabe, 2, 5, Mitsubishi Tanabe Pharma, 2, 5, MSD, 5, 8, Novartis, 2, 5, 8, 9, Patent, 9, Patent issued, 9, Pfizer, 2, 5, 8, Pharmacyclics, 2, 5, Roche, 5, 8, 9, Sanofi, 2, 5, Sinoxa, 2, 5, Target Bio Science, 5, Target BioScience, 5, UCB, 2, 5, 9, UCB in the area of potential treatments of scleroderma and its complications, 2, 5; G. Kania, None.

To cite this abstract in AMA style:

Rufer C, Rudnik M, Uhtjärv S, Stellato M, Renoux F, Distler O, Kania G. Altered Inflammatory Response of Macrophages in the Fosl-2 Transgenic Mouse Model of Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/altered-inflammatory-response-of-macrophages-in-the-fosl-2-transgenic-mouse-model-of-systemic-sclerosis/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/altered-inflammatory-response-of-macrophages-in-the-fosl-2-transgenic-mouse-model-of-systemic-sclerosis/